{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:36:18Z","timestamp":1789054578236,"version":"build-2803163510"},"reference-count":23,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2016]]},"DOI":"10.1536\/ihj.15-483","type":"journal-article","created":{"date-parts":[[2016,7,10]],"date-time":"2016-07-10T22:04:35Z","timestamp":1468188275000},"page":"496-502","source":"Crossref","is-referenced-by-count":10,"title":["A Safety and Efficacy Study of Tolvaptan Following Open Heart Surgery in 109 Cases"],"prefix":"10.1536","volume":"57","author":[{"given":"Takanori","family":"Kono","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Surgery, Clinical Research Institute, Kyushu Medical Center, National Hospital Organization of Japan"},{"name":"Department of Cardiovascular Surgery, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiki","family":"Tayama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Clinical Research Institute, Kyushu Medical Center, National Hospital Organization of Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetsugu","family":"Hori","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Clinical Research Institute, Kyushu Medical Center, National Hospital Organization of Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Clinical Research Institute, Kyushu Medical Center, National Hospital Organization of Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yamaki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Clinical Research Institute, Kyushu Medical Center, National Hospital Organization of Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Gheorghiade M, Gattis WA, O\u2019Connor CM, <i>et al<\/i>. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963-71.","DOI":"10.1001\/jama.291.16.1963"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Konstam MA, Gheorghiade M, Burnett Jr JC, <i>et al<\/i>. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-31.","DOI":"10.1001\/jama.297.12.1319"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Matsuzaki M, Hori M, Izumi T, Fukunami M. Efficacy and safety tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST Study). Cardiovasc Drugs Ther 2011; 25: S33-45.","DOI":"10.1007\/s10557-011-6304-x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Watanabe K, Dohi K, Sugimoto T, <i>et al<\/i>. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol 2012; 60: 462-9.","DOI":"10.1016\/j.jjcc.2012.09.002"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Matsue Y, Suzuki M, Seya M, <i>et al<\/i>. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol 2013; 61: 169-74.","DOI":"10.1016\/j.jjcc.2012.08.020"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Shirakabe A, Hata N, Yamamoto M, <i>et al<\/i>. Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure. Circ J 2014; 78: 911-21.","DOI":"10.1253\/circj.CJ-13-1255"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Suzuki S, Yoshida A, Yamaki T, <i>et al<\/i>. Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide. J Clin Pharmacol 2013; 53: 1277-85.","DOI":"10.1002\/jcph.197"},{"key":"8","unstructured":"8. Nodari S, Jao GT, Chiong JR. Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients. Int J Nephrol Renovasc Dis 2010; 3: 51-60."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Gheorghiade M, Konstam MA, Burnett JC Jr, <i>et al<\/i>. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007; 297: 1332-43.","DOI":"10.1001\/jama.297.12.1332"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gheorghiade M, Rossi JS, Cotts W, <i>et al<\/i>. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch Intern Med 2007; 167: 1998-2005.","DOI":"10.1001\/archinte.167.18.1998"},{"key":"11","unstructured":"11. Sezai A, Shiono M. Treatment strategies of heart failure after open heart surgery. Fluid Manag Renaiss 2013; 3: 160-7. (Japanese)"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Yoshitake I, Hata H, Hata M, <i>et al<\/i>. Efficacy of tolvaptan for postoperative congestive heart failure after cardiac surgery: a case of mitral valve replacement due to acute mitral regurgitation after coronary intervention. J Jpn Coron Assoc 2014; 20: 209-13. (Japanese)","DOI":"10.7793\/jcoron.20.13-00036"},{"key":"13","unstructured":"13. Kondo T, Hoshino J, Fukada Y, Hirota M, Takahashi Y, Isomura T. Effectiveness of tolvaptan for postoperative heart failure in a patient with combined valvular disease and pulmonary hypertension. Kyobu Geka 2014; 67: 117-20. (Japanese)"},{"key":"14","unstructured":"14. Sato M, Nakayama Y, Kawasaki H, Mukae Y. Clinical effects of tolvaptan for patients with stage 4\u20135 chronic kidney disease in cardiac surgery. Kyobu Geka 2014; 67: 186-9. (Japanese)"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hirleman E, Larson DF. Cardiopulmonary bypass and edema: physiology and pathophysiology. Perfusion 2008; 23: 311-22. (Review)","DOI":"10.1177\/0267659109105079"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Jochberger S, Mayr VD, Luckner G, <i>et al<\/i>. Serum vasopressin concentrations in critically ill patients. Crit Care Med 2006; 34: 293-9.","DOI":"10.1097\/01.CCM.0000198528.56397.4F"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Imamura T, Kinugawa K, Shiga T, <i>et al<\/i>. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease. Circ J 2013; 77: 397-404.","DOI":"10.1253\/circj.CJ-12-0971"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kinugawa K, Sato N, Inomata T, Shimakawa T, Iwatake N, Mizuguchi K. Efficacy and safety of tolvaptan in heart failure patients with volume overload. Circ J 2014; 78: 844-52.","DOI":"10.1253\/circj.CJ-66-0093"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Mathew JP, Fontes ML, Tudor IC, <i>et al<\/i>. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004; 291: 1720-9.","DOI":"10.1001\/jama.291.14.1720"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Auer J, Weber T, Berent R, Lamm G, Eber B. Serum potassium level and risk of postoperative atrial fibrillation in patients undergoing cardiac surgery. J Am Coll Cardiol 2004; 44: 938-9.","DOI":"10.1016\/j.jacc.2004.05.035"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Torres VE, Chapman AB, Devuyst O, <i>et al<\/i>. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407-18.","DOI":"10.1056\/NEJMoa1205511"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Patti G, Chello M, Candura D, <i>et al<\/i>. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia after cardiac surgery) study. Circulation 2006; 114: 1455-61.","DOI":"10.1161\/CIRCULATIONAHA.106.621763"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Almassi GH, Schowalter T, Nicolosi AC, <i>et al<\/i>. Atrial fibrillation after cardiac surgery: a major morbid event? Ann Surg 1997; 204: 501-11.","DOI":"10.1097\/00000658-199710000-00011"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/57\/4\/57_15-483\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T18:09:36Z","timestamp":1498327776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/57\/4\/57_15-483\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.15-483","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}